 |
1 Disease |  |
4 Trials |
|
4 Trials |  |
263 News |  |
| «1234 |
- ||||||| Lybalvi (olanzapine/samidorphan) / Alkermes
Trial completion, Trial primary completion date: A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study) (clinicaltrials.gov) - Jul 11, 2017
P3, N=403, Completed, Sponsor: Alkermes, Inc.
Active, not recruiting --> Completed | Trial primary completion date: Jan 2018 --> May 2017
- |||||||||| Lybalvi (olanzapine/samidorphan) / Alkermes
New P3 trial: Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 (clinicaltrials.gov) - Jun 27, 2017
P3, N=500, Enrolling by invitation, Sponsor: Alkermes, Inc.
- |||||||||| Lybalvi (olanzapine/samidorphan) / Alkermes
New P3 trial: Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder (clinicaltrials.gov) - Jun 15, 2017
P3, N=250, Recruiting, Sponsor: Alkermes, Inc.
- ||||| Lybalvi (olanzapine/samidorphan) / Alkermes
Enrollment closed: A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study) (clinicaltrials.gov) - May 5, 2017
P3, N=403, Active, not recruiting, Sponsor: Alkermes, Inc.
Active, not recruiting --> Completed | Trial primary completion date: Jan 2018 --> May 2017 Recruiting --> Active, not recruiting
- Lybalvi (olanzapine/samidorphan) / Alkermes
Trial primary completion date: An Insulin Sensitivity Study in Healthy Subjects (clinicaltrials.gov) - May 1, 2017
P1, N=50, Recruiting, Sponsor: Alkermes, Inc.
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2017 --> Aug 2017
- |||| Lybalvi (olanzapine/samidorphan) / Alkermes
Trial completion: A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder (clinicaltrials.gov) - Mar 10, 2017
P2, N=300, Completed, Sponsor: Alkermes, Inc.
Trial primary completion date: Mar 2017 --> Aug 2017 Active, not recruiting --> Completed
- |||| Lybalvi (olanzapine/samidorphan) / Alkermes
Enrollment status: A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia (clinicaltrials.gov) - Dec 22, 2016
P3, N=390, Enrolling by invitation, Sponsor: Alkermes, Inc.
Active, not recruiting --> Completed Recruiting --> Enrolling by invitation
- | Lybalvi (olanzapine/samidorphan) / Alkermes
New P1 trial: An Insulin Sensitivity Study in Healthy Subjects (clinicaltrials.gov) - Oct 4, 2016
P1, N=50, Recruiting, Sponsor: Alkermes, Inc.
- | Lybalvi (olanzapine/samidorphan) / Alkermes
Trial completion: A Phase 1 Safety Study in Adults With Schizophrenia (clinicaltrials.gov) - Sep 21, 2016
P1, N=42, Completed, Sponsor: Alkermes, Inc.
Recruiting --> Enrolling by invitation Recruiting --> Completed
- |||||||||| Lybalvi (olanzapine/samidorphan) / Alkermes
New P3 trial: A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia (clinicaltrials.gov) - Aug 18, 2016
P3, N=540, Enrolling by invitation, Sponsor: Alkermes, Inc.
- | Lybalvi (olanzapine/samidorphan) / Alkermes
New P1 trial: A Phase 1 Safety Study in Adults With Schizophrenia (clinicaltrials.gov) - Jun 18, 2016
P1, N=42, Recruiting, Sponsor: Alkermes, Inc.
- ||| Lybalvi (olanzapine/samidorphan) / Alkermes
Enrollment closed, Enrollment change: A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder (clinicaltrials.gov) - May 18, 2016
P2, N=300, Active, not recruiting, Sponsor: Alkermes, Inc.
Recruiting --> Completed Recruiting --> Active, not recruiting | N=450 --> 300
- |||||||||| Lybalvi (olanzapine/samidorphan) / Alkermes
New P3 trial: A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study) (clinicaltrials.gov) - Feb 29, 2016
P3, N=540, Recruiting, Sponsor: Alkermes, Inc.
- |||||| Lybalvi (olanzapine/samidorphan) / Alkermes
Enrollment open: A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia (clinicaltrials.gov) - Feb 29, 2016
P3, N=390, Recruiting, Sponsor: Alkermes, Inc.
Recruiting --> Active, not recruiting | N=450 --> 300 Not yet recruiting --> Recruiting
- |||||||||| Lybalvi (olanzapine/samidorphan) / Alkermes
New P3 trial: A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia (clinicaltrials.gov) - Feb 1, 2016
P3, N=390, Not yet recruiting, Sponsor: Alkermes, Inc.
- |||||||||| Lybalvi (olanzapine/samidorphan) / Alkermes
New P3 trial: A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study) (clinicaltrials.gov) - Dec 18, 2015
P3, N=390, Recruiting, Sponsor: Alkermes, Inc.
- Lybalvi (olanzapine/samidorphan) / Alkermes, samidorphan (ALKS 33) / Alkermes
Trial completion: A Study of ALKS 3831 in Adults With Schizophrenia (clinicaltrials.gov) - May 2, 2015
P2, N=309, Completed, Sponsor: Alkermes, Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Lybalvi (olanzapine/samidorphan) / Alkermes, samidorphan (ALKS 33) / Alkermes
Enrollment closed: A Study of ALKS 3831 in Adults With Schizophrenia (clinicaltrials.gov) - Sep 12, 2014
P2, N=350, Active, not recruiting, Sponsor: Alkermes, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Lybalvi (olanzapine/samidorphan) / Alkermes
New P2 trial: A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder (clinicaltrials.gov) - Jun 13, 2014
P2, N=450, Recruiting, Sponsor: Alkermes
- ||||| Lybalvi (olanzapine/samidorphan) / Alkermes, samidorphan (ALKS 33) / Alkermes
New P2 trial: A Study of ALKS 3831 in Adults With Schizophrenia (clinicaltrials.gov) - Jul 17, 2013
P2, N=350, Recruiting, Sponsor: Alkermes